HISTORY
2019 ~
Entry to total health care and well-being industry from focusing on materials for medical treatment
2021
Permission for Graft/Prosthesis, Biomaterial(for export)- Graft/Prosthesis,Biomaterial for joint
- Global Export Power Company Selected
- Establishing a foothold for Botox business by signing Ora Bio investment and joint management contracts
- Injection and anti-adhesion drugs approved by the UK Medicines Regulator (MHRA).
- Establishing a foothold for the biobetter business by signing a contract for ubi protein Co., Ltd. technology cooperation.
- Listed in KOSDAQ(21.09)
2020
- Approval of GMP and CE at Seongnam Plant 2
- Entry to the project in hainan island of china as the only domestic company (april 2020)
- China’s Gangdong New District Signature Ceremony (Dec. 2020)
- Bio+ Dew™ KFDA Item permission
2019
- Mdsapcertification : filler, anti-adhesive barrier agent
- Synovial fluid replacement export license (19. 3.)
- Synovial fluid replacement irb
- Interblock( anti adhesive barrier agent) kfda completion (19. 2.) / ce certification (19. 2.)
- Establishment of 5 branches in overseas (dubai, new delhi)
- Gyeonggido seongnam 2nd plant and r&d center expansion / business centert gyeonggido seognam (19.10)
2008 ~ 2018
Expansion of R&D intrastructure and construction of cutting-edge manufacturing facilities.
2016 ~ 2018
- Global leader in biomaterials
- Entry to total health care and well-being industry from focusing on materials for medical treatment
- Interblock (anti adhesive barrier agent) irb approved (17. 5.)
- Interblock (anti adhesive barrier agent) export license (16. 10.)
2014 ~ 2015
- Hyaldew® kfda item PERMISSION
- Skinplus-hyal® kfda item PERMISSION
- Skinplus-hyal® kgmp(FORMERLY, kfda)
- Skinplus-hyal®, deneb® ce CERTIFICATION
- Skinplus-hyal® completed clinical trials (seoul national university hospital – seoul, bundang)
2013
- Completion OF daejeon plant 1 AND r&d center
2010 ~ 2011
- Manufacturing and product license (for export)
2008 ~ 2009
- Skinplus-hyal® completed biocompatibility and safety test / completed preclinical test
2003 ~ 2007
Development of products based on polymeric olysaccharide (hyaluronic acid)
Completed various and differentiated world class ha filler lineup
2003
- Additional development in applied products based on bio-materials & business expansion
- Expansion of r&d intrastructure and construction of cutting-edge manufacturing facilities
- Selection of ha based filler and completed development
- Performed variety of filler research including collagen and microbead filler
- Establishment of bioplus co., ltd.
